Cargando…
Anti-HIV drug repurposing against SARS-CoV-2
A novel severe acute respiratory syndrome human coronavirus (SARS HCoV) was identified from respiratory illness patients (named SARS-CoV-2 by ICTV) in December 2019 and has recently emerged as a serious threat to world public health. However, no approved drugs have been found to effectively inhibit...
Autores principales: | Sang, Peng, Tian, Shu-Hui, Meng, Zhao-Hui, Yang, Li-Quan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052367/ https://www.ncbi.nlm.nih.gov/pubmed/35493667 http://dx.doi.org/10.1039/d0ra01899f |
Ejemplares similares
-
Potential repurposed SARS-CoV-2 (COVID-19) infection drugs
por: Abuo-Rahma, Gamal El-Din A., et al.
Publicado: (2020) -
Repurposing of Drugs for SARS-CoV-2 Using Inverse Docking Fingerprints
por: Jukič, Marko, et al.
Publicado: (2021) -
Pharmacophore Modelling-Based Drug Repurposing Approaches for SARS-CoV-2 Therapeutics
por: Rampogu, Shailima, et al.
Publicado: (2021) -
Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
por: Aherfi, Sarah, et al.
Publicado: (2021) -
Thermodynamic and structural insights into the repurposing of drugs that bind to SARS-CoV-2 main protease
por: Wan, Shunzhou, et al.
Publicado: (2021)